Astellas Pharma Gmbh

Kotobuki Pharmaceutical Co Ltd

Makoto Kasai

Noriyuki Kawano

Satoshi Miyamoto

Ryota Shiraki

Masakazu Imamura

Keita Nakanishi

Ryo Mizoguchi

Takenori Kimura

Junya Ohmori

Noritaka Hamada

Kousuke Komenoi

Atsushi Nakamura

Anytime obtained is uniform crystal of N-(4-fluorophenyl)-N'-phenyl-N&#x2033;-(pyrimidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine (compound A) and/or N,N&#x2032;-bis (4-fluorophenyl)-N&#x2033;-(pyrimidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine (compound B) as a medicament or a starting material for the preparation of the medicament, and provided are a fumarate of the compound A and/or the compound B having excellent stability and a novel crystal thereof. A salt of the compound A and/or the compound B with fumaric acid enables uniform crystal to be anytime obtained, and thus, it is a compound that is very useful as a medicament or a starting material for the preparation of the medicament having excellent stability.

Salt of 1,3,5-triazine-2,4,6-triamine derivative

The present invention provides a method for producing a C-glycoside derivative, which can produce the C-glycoside derivative at a high yield and at a low cost, which conforms to environmental protection, and which is applicable industrially. The C-glycoside derivative is useful for treating and preventing diabetes such as insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes) and the like and various diabetes-related diseases including insulin-resistant diseases and obesity.

Method for producing C-glycoside derivative and intermediate for synthesis thereof

Growing community of inventors

Chuo-ku, Japan

Makoto Kasai